TALOPH(SH:600222) Cai Jing Wang·2025-09-17 09:03Core Insights - The company held a performance briefing for the first half of 2025 on September 17, where it addressed inquiries regarding the increase in gross margin for its traditional Chinese medicine (TCM) decoction pieces business [1] - Management highlighted that the fluctuation in medicinal herb prices was influenced by various external factors such as natural conditions, economic environment, and market supply-demand relationships [1] - The company reported a revenue of 762 million yuan for the first half of 2025, reflecting a year-on-year decline [1] Revenue and Financial Performance - The company achieved a revenue of 762 million yuan in the first half of 2025, which represents a year-on-year decrease [1] - Sales dispatches were affected due to the uneven progress of provincial drug standardization, despite the company's main products being selected in the national collection of traditional Chinese medicine [1] Product Development and Strategy - The company is focusing on self-initiated projects that are progressing rapidly, particularly in the development of modified new drugs with clear clinical value, high technical barriers, and good patient compliance [1] - The self-initiated projects cover various therapeutic areas including respiratory, digestive, infectious diseases, tumors, and mental health [1] Market Conditions - Management noted that the company is closely monitoring the prices of medicinal herbs due to the diverse range of herb varieties and specifications [1] - The company is leveraging the "Tongjun Hall Digital Center" to enhance the traceability system for medicinal materials [1]